The Head and Neck Oncology Program (HNOP) is a comprehensive program in head and neck cancer research that includes a multidisciplinary team of Investigators In basic, clinical, behavioral, population and translational research. The program consists of 44 members from 11 departments in five schools across the University of Michigan. The HNOP's direct cost funding has increased by 60% over this grant period, to over $5 million of which $2 is in NCI funding, including a Head and Neck SPORE. Program members published 293 papers during this grant period, 22.5% of which demonstrated intra-programmatic and 33.4% Inter-programmatic collaborations. Many members of this program also hold joint membership in other Cancer Center basic science or prevention programs which integrate additional fundamental research into the underlying mechanisms of head and neck cancer behavior and treatment. The major research themes of the HNOP are to; 1. Identify mechanisms of carcinogenesis and progression 2. Determine the molecular determinants of treatment response 3. Characterize the immunobiology of the tumor microenvironment to better modulate the immune system as a therapeutic modality 4. Characterize the role of cancer stem cells in tumor progression, Invasion, metastasis and resistance to treatment 5. Define new treatment combinations based on laboratory and clinical studies that define new biomarkers for individualized therapies 6. Define organ preservation strategies in head and neck cancer 7. Develop and implement novel reconstruction and rehabilitation techniques for head and neck cancer patients This program has undergone considerable recruitment over this grant period with 18 new faculty members, and a renewed/expanded emphasis on translational research that should become fully realized over the next grant cycle.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-25
Application #
8559859
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
25
Fiscal Year
2013
Total Cost
$81,662
Indirect Cost
$34,428
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Rosselli-Murai, Luciana K; Yates, Joel A; Yoshida, Sei et al. (2018) Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. J Cell Sci 131:
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768
Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54
Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481
Chockley, Peter J; Chen, Jun; Chen, Guoan et al. (2018) Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest 128:1384-1396

Showing the most recent 10 out of 1493 publications